Call Me
Back

[bwp-recaptcha bwp-recaptcha-93]

United Kingdom: +44 20 3773 8602
Sweden: +46812410070
Norway: +4721930512
New Zealand: +6448302404
Israel: +97223740103
Austria: +43720775041
Australia: +61280730589
Spain: +34933938161
South Africa: +27115682351
Canada: +14382289855
USD/CAD 1.24275 21:00 17.01 GBP/CHF 1.33424 20:30 17.01 CHF/JPY 115.402 19:30 17.01 OIL-MAR18 (BRENT) 69.450 19:00 17.01 GOLD 1339.425 19:00 17.01 COCA COLA 46.695 15:30 17.01 GAZPROM 148.825 14:30 17.01 MICEX 2271.540 14:30 17.01 EUR/USD 1.22226 14:15 17.01 USD/RUB 56.868 14:00 17.01 AUD/CHF 0.76725 14:00 17.01 AUD/USD 0.79691 13:00 17.01 GBP/USD 1.37789 13:00 17.01 EUR/RUB 69.412 13:00 17.01 USD/ZAR 12.32927 13:00 17.01 EUR/JPY 135.230 12:45 17.01 GBP/JPY 152.802 12:30 17.01 EUR/USD 1.22120 12:30 17.01 EUR/CAD 1.51884 12:30 17.01 GBP/RUB 78.2879 12:30 17.01 USD/ZAR 12.33100 12:30 17.01 BITCOIN 9937.850 12:00 17.01 GBP/USD 1.37858 12:00 17.01 BANCO SANTANDER 5.891 12:00 17.01 GBP/USD 1.37962 11:45 17.01 GBP/USD 1.37984 11:30 17.01 LITECOIN 159.085 11:00 17.01 BITCOIN 9767.900 11:00 17.01 USD/CHF 0.96352 10:00 17.01 GOLD/EUR 1091.395 09:45 17.01

Market Review

DAILY MARKET OVERVIEW
Today's Top Market Headlines – Jan 26, 2017
Britain's economy beats forecasts with 0.6% growth in the last quarter

The Gross Domestic Product released by the National Statistics is a measure of the total value of all goods and services produced by the UK and it is considered as a broad measure of the UK economic activity. The quarterly GDP for the U.K. rose steadily by 0.6 percent. Britain’s service sector drove the most growth in the last quarter, expanding by 0.8%, while construction while industrial output lagged behind. Following falls in Quarter 3 (July to Sept) 2016, construction and production provided modest positive contributions to the GDP growth in Quarter 4 2016. Overall, UK GDP was estimated to have increased by 2.0% during 2016.  .

European Markets head higher on solid data…

European markets moved higher on Thursday morning extending yesterday’s profits that boosted the Dow Jones industrial average to an all-time high. Banking and healthcare stocks were the best performers as investors remained confident that President Donald Trump will carry on implementing his campaign pledges, including cutting taxes, business protectionism and de-regulation. It is also worth noting that the British Banker’s Association also announced Thursday that the number of mortgages approved by British bank hit a nine-month high in December.

Biotech shares advance in the face of the FDA decision next month

January has been a rather slow month in terms of drug approvals. Specifically, Synergy Pharmaceuticals Inc.’s (SGYP) Trulance for the treatment of Chronic Idiopathic Constipation in adult patients, and Allergan plc’s (AGN) Rhofade cream for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults were the only drugs that won the FDA’s green light in January. The iShares of Nasdaq Biotechnology ETF (IBB) added an impressive 4.7% this month, outperforming the S&P 500 by 43%.

Actelion shares skyrocket on a $30 billion takeover deal with JNJ

Shares of Actelion Ltd. skyrocketed by around 21 percent in the morning trading after the Swiss biotechnology firm on Thursday agreed to a $30 billion takeover by drug major Johnson & Johnson. Immediately prior to the completion of the acquisition, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly standalone Swiss biopharmaceutical company. Under the deal terms, Johnson & Johnson will launch a cash buyout offer in Switzerland to acquire Actelion for $280 per share, payable in U.S. dollars, which equates to 280.08 Swiss francs per share.